Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?

Wild, Sabine R de; Moyakine, Andre Vadimovich; Vleuten, C.J.M. van der

doi:10.1111/pde.13941

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly, parents still suffer from the intense experiences related to having an infant with IH. Parents of infants with proliferating IH report a high burden of disease, elevated parenting stress, and decreased quality of life [21,22,25,52]. They have to cope with difficulties of having an infant with a medical condition and may face negative responses from bystanders to the visible difference of their infant.…”

Section: Long-term Mentalmentioning

confidence: 99%

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Hermans,

Schappin,

de Laat

et al. 2024

Dermatology

View full text Add to dashboard Cite

Background: Infants with infantile hemangioma (IH) have been effectively treated with propranolol or atenolol. Concerns were raised about the mental health of these children at school-age, due to central nervous system effects of propranolol and visible nature of IH. Objective: This study aimed to compare the mental health at school-age of children treated with propranolol to children treated with atenolol for IHs, and their parents. Methods: This two-center cross-sectional study included children aged ≥6 years and treated with either propranolol or atenolol for IH during infancy. Children’s outcomes were performance-based affect recognition (NEPSY-II-NL), and parent-reported emotional and behavioral functioning (CBCL), and health-related quality of life (KIDSCREEN-27). Parents’ outcome was parenting stress (OBVL). Results: Data of 105 children (36 propranolol, 69 atenolol; 6.0 to 11.8 years) were analyzed. Mental health outcomes did not differ between both beta-blocker groups. Although overall functioning was in line with norms, children presented specific problems concerning affect recognition, and parent-reported attention and social quality of life. Parents showed increased physical symptoms, depressive symptoms, and parent-child relationship problems. Conclusion: No difference in mental health at school-age was found between children treated with propranolol or atenolol for IH. Although few overall mental health problems were found, specific problems require follow-up. Follow-up of children should be directed towards affect recognition, attention, and social functioning in daily life. Problems reported by parents could be ameliorated by mental health support during and after their infant’s beta-blocker treatment.

show abstract

Section: Long-term Mentalmentioning

confidence: 99%

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Hermans,

Schappin,

de Laat

et al. 2024

Dermatology

View full text Add to dashboard Cite

show abstract

Infantile Hemangioma: An Updated Review

Leung

Lam

Leung

et al. 2021

CPR

View full text Add to dashboard Cite

Background: Infantile hemangiomas are the most common vascular tumors of infancy affecting up to 12% of infants by the first year of life. Objective: To familiarize physicians with the natural history, clinical manifestations, diagnosis, and management of infantile hemangiomas. Methods: A Pubmed search was conducted in November 2019 in Clinical Queries using the key term "infantile hemangioma". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews published within the past 20 years. Only papers published in the English literature were included in this review. The information retrieved from the above search was used in the compilation of the present article. Results: The majority of infantile hemangiomas are not present at birth. They often appear in the first few weeks of life as areas of pallor, followed by telangiectatic telangiectatic or faint red patches. They then grow rapidly in the first 3 to 6 months of life. Superficial lesions are bright red, protuberant, bosselated or with a smooth surface, and sharply demarcated. Deep lesions are bluish and dome-shaped. Infantile hemangiomas continue to grow until 9 to 12 months of age, at which time the growth rate slows down to parallel the growth of the child. Involution typically begins by the time the child is a year old. Approximately 50% of infantile hemangiomas will show complete involution by the time a child reaches age 5; 70% will have disappeared by age 7; and 95% will have regressed by 10 to 12 years of age. The majority of infantile hemangiomas require no treatment. Treatment options include oral propranolol, topical timolol, and oral corticosteroids. Indications for active intervention include hemorrhage unresponsive to treatment, impending ulceration in areas where serious complications might ensue, interference with vital structures, life- or function-threatening complications, and significant disfigurement. Conclusion: Treatment should be individualized, depending upon the size, rate of growth, morphology, number and location of the lesion (s), existing or potential complications, benefits and adverse events associated with the treatment, age of the patient, level of parental concern, and the physician's comfort level with the various treatment options. Currently, oral propranolol is the treatment of choice for high-risk and complicated infantile hemangiomas. Topical timolol may be considered for superficial infantile hemangiomas which need to be treated and for complicated infantile hemangiomas in patients at risk for severe adverse events from oral administration of propranolol.

show abstract

The Pelvic and Sacral Splanchnic Nerves – Identification by Dissection, Trajectory

Goidescu

Dogaru

Enyedi

et al. 2022

Maedica

View full text Add to dashboard Cite

Backround:Infantile haemangiomas are the most common benign tumours of the child with clinical manifestations in the first two years of life, which is an additional cause of parents’ concerns. Objective:This study describes the first stage in elaborating a specific instrument to evaluate the quality of life of both patients with infantile haemangioma under two years of age and their parents, adapted to the reality of the Romanian context. Methods:Items were generated from a literature review – from both the current generic pediatricians’ instruments and specific tools in dermatology for assessing quality of life and the existing consensus among experts – as well as from a qualitative analysis of parents’ concerns. The instrument was piloted on a group of patients’ relatives. Results:We have developed a 28-item specific infantile haemangioma quality of life questionnaire with four sub-scales to assess physical health, the social function of the child, parents’ emotional health and the social function of parents. Demographic data and clinical features (meanings of symptoms and outcomes) that have an impact on the quality of life were obtained. Conclusion:It is important to be able to measure and compare the quality of life of both patients with infantile haemangioma and their parents for adapting the treatment to the specific needs of patients and their family. The effectiveness of new therapeutic options which are especially useful for infants with haemangiomas can be checked by using the questionnaire as a measure of patient-reported outcome. The questionnaire developed by us was well accepted by the patients’ parents.

show abstract

Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?

Cited by 3 publications

References 4 publications

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents

Infantile Hemangioma: An Updated Review

The Pelvic and Sacral Splanchnic Nerves – Identification by Dissection, Trajectory

Contact Info

Product

Resources

About